Shoulder Innovations Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
We're going to get started with our next session. I'm Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jefferies, and I'm pleased to host this session with management from Shoulder Innovations. We have Rob Ball, the CEO, who will take us through some of the company's strategy and their innovative shoulders.
It's great. Thanks for having me, Matt.
Thanks for coming, Rob. Maybe for those newer to the story, particularly with you having been public for just about a year, could you talk a little bit about the shoulder market, your competitive position within it, and some of the differentiation that you bring to the market?
Yep. Yeah, of course. Shoulder arthroplasty really is a unique sub-segment of the orthopedic marketplace in the sense that it's sizable. Think about a $2.5 billion U.S. market growing at low double-digit percent, which really positions it as the best market in orthopedics. So we're delighted to be in that space. When you think about who performs shoulder arthroplasty, there's about 15,000 surgeons, at least in the U.S., that perform shoulder arthroplasty. We're focused on around the 1,800 that we characterize as high-volume shoulder surgeons. So what we define that as is more than 35. They carry out a majority of the shoulder replacements, and our commercial strategy is to focus specifically on those high-volume surgeons. Of course, we approach those surgeons with very innovative products.
We're very much known for the InSet glenoid, which is an innovative device which solves the main problem in anatomic shoulder arthroplasty, which is loosening of the scapular glenoid component. It's common that at about five years, it's either frankly loose or shows the signs of loosening on radiological films. We have a device that both saves times in the operating room and solves for the mechanism of action of that difficulty. We also present both reverse shoulder arthroplasty. Just backing up, shoulder arthroplasty makes up of two main types of components, anatomic or reverse. Reverse is when you have both arthritis and deficiency of the rotator cuff, and you'll put the ball on the scapular side of the joint instead of the humeral side of the joint. We carry, we market both types of products.
On the reverse side, from an innovation standpoint, we bring a lateral-lateral set of biomechanics, which is unique to the marketplace, provides early positive range of motion for patients, and we've been kind of excited to engage surgeons with that style. Anyway, that's a brief overview.
Great. Maybe you could talk more about the market first and just why it continues to grow. What are the growth drivers? We've heard other orthopedic companies, hip and knee, talk about some slowing, but not really in extremities and in shoulder, where there's a lot of room for continued penetration.
Yeah, for sure. We're not seeing slowing in arthroplasty. I think there's a few drivers here. One is we've seen material innovation in the space. We didn't have reverse shoulder arthroplasty available to us in the U.S. until the early 2000s. Reverse has now grown to be 70% of procedures. That's been a rapid kind of change in the marketplace. Think about that in terms of 70% of the market was not well represented kind of 20 years ago. That's been a rapid pace of growth. Of course, in that rapid pace of growth, you can understand there's been a lot of innovation, learning about that procedure, understanding the outcomes and the difficulties that you may face. As that kind of learning has happened, it's also produced much better outcomes and a much better reputation in the marketplace.
When you get to supply-demand dynamics, you think about the number of patients that surgeons see for knee pain is about the same number as surgeons see for shoulder pain. There just happens to be about three times as many knee replacements as shoulder replacements. You can understand that supply-demand dynamic is there. We also find shoulder arthroplasty being a highly specialized part of the marketplace. Again, most of the procedures carried out by just those high-volume shoulder specialists. There are a robust number of fellowships, and those are popular among new surgeons because shoulder arthroplasty is technically challenging, intellectually interesting, and from a lifestyle characteristic, it is quite interesting. You see a nice inflow of surgeons seeking to specialize in the space as well.
Yeah, and you mentioned the InSet glenoid, which is a big differentiator for you. Maybe you could expound a little on how that works, why it is differentiated, your clinical evidence, and how important that has been for you to convert surgeons from big incumbents, which you have been successful at.
Yeah, it is great. Thanks, Matt. As I mentioned, the main problem in anatomic shoulder arthroplasty is the loosening of that polymer device away from the scapula. When you perform an anatomic replacement, you will prepare the bone or machine a surface on the scapula and apply a polyethylene liner in order to replace or resurface that articular surface. The challenge with that is what is created is what is called a rocking horse motion. We did not discover or prove that. That was well understood before we existed as a company, but it is essentially the idea that as the humeral head translates across that polymer surface, it creates a rocking action of that device and brings it loose away from the glenoid.
We innovated what is called the InSet glenoid, and what we do is we change the shape of the device to be cylindrical in nature and provide for the ability to machine a cylindrical pocket into the glenoid bone. That provides a buttress of bone that fully surrounds the implant and eliminates that rocking horse motion, or effectively eliminates it, which is the mechanism of action, if you will, of failure. We have proven in several peer-reviewed publications in JSES, the main shoulder arthroplasty journal worldwide, that both the mechanism of action has been solved for and the clinical outcomes. We have essentially nine-year, 100% survivorship data. No one has produced data like that before. It has been a very successful technology.
Obviously, as a new company, presenting that type of clinical evidence in a value analysis committee environment has been very powerful for us and has effective for us to change the minds of many surgeons.
Maybe just for context, maybe you could compare the 100% survivorship to what you would typically see from a competitive device.
Yeah, at a nine-year survivorship, you're going to see under 80% for sure. You'll see publications, frankly, in the 40s. Obviously, there's many publications, but very, very low.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
